March 27, 2025 Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
February 27, 2025 Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
February 20, 2025 Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
January 29, 2025 Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
November 26, 2024 Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 13, 2024 Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
November 7, 2024 Ironwood Pharmaceuticals Reports Third Quarter 2024 Results Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
October 28, 2024 Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
October 24, 2024 Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
August 29, 2024 Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
August 8, 2024 Ironwood Pharmaceuticals Reports Second Quarter 2024 Results Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
July 25, 2024 Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
May 30, 2024 Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 21, 2024 Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
May 9, 2024 Ironwood Pharmaceuticals Reports First Quarter 2024 Results Ironwood Pharmaceuticals Reports First Quarter 2024 Results
May 6, 2024 Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
May 1, 2024 Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024 Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
April 25, 2024 Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
